| Description : |
IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. |
| Source : |
E. coli |
| Species : |
Human |
| Form : |
Sterile Filtered White lyophilized (freeze-dried) powder. |
| Bio-activity : |
The ED50 was determined by its ability to inhibit IGF-II induced proliferation of MCF-7. The expected ED50 for this effect is ≤ 0.2 μg/mL in presence of 15 ng/mL of human IGF-II, corresponding to a Specific Activity of ＞5000 IU/mg. |
| Molecular Mass : |
28.8 kDa protein consisting of 264 amino acid residues.. |
| Protein Length : |
264 |
| AA Sequence : |
GASSGGLGPVVRCEPCDARALAQCA PPPAVCAELVREPGCGCCLTCALSE GQPCGIYTERCGSGLRCQPSPDEAR PLQALLDGRGLCVNASAVSRLRAYL LPAPPAPGNASESEEDRSAGEVESP SVSSTHRVSDPKFHPLHSKIIIIKK GHAKDSQRYKVDYESQSTDTQNFSS ESKRETEYGPCRREMEDTLNHLKFL NVLSPRGVHIPNCDKKGFYKKKQCR PSKGRKRGFCWCVDKYGQPLPGYTT KGKEDVHCYSMQSK |
| Endotoxin : |
Less than 1 EU/mg of rHuIGF-BP3 as determined by LAL method. |
| Purity : |
>98% by SDS-PAGE and HPLC analyses. |
| Storage : |
This lyophilized preparation is stable at 2-8 centigrade, but should be kept at -20 centigrade for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 centigrade. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 to -70 centigrade. Avoid repeated freeze/thaw cycles. |
| Storage Buffer : |
Lyophilized from a 0.2mm filtered concentrated solution in PBS, pH 7.4. |
| Reconstitution : |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 centigrade. Further dilutions should be made in appropriate buffered solutions. |
